Approach to the patient with migraine.
Women with migraine often experience a worsening of symptoms at menopause. Use of exogenous estrogens is not helpful and may even exacerbate the condition. Although initial pharmacologic management generally is focused on control of individual headaches, attempts to stabilize the underlying migraine mechanism through serotonin receptor downregulation are likely to provide a better outcome.
Raskin
N H
NH
Department of Neurology, University of California, School of Medicine, San Francisco, California, USA.
Baringer
J R
JR
D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000983:Antipyrine; D002697:Chloral Hydrate; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004878:Ergotamine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause; D008744:Methylamines; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D018170:Sumatriptan / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D004338:Drug Combinations; D008744:Methylamines; D017366:Serotonin Receptor Agonists; D014665:Vasodilator Agents; D002697:Chloral Hydrate; D018170:Sumatriptan; D014700:Verapamil; D004878:Ergotamine; D000983:Antipyrine; C008192:isometheptene; C007333:dichloralantipyrine